A team of US specialists, including a Turkish researcher, has successfully developed a vaccine aimed at preventing the spread of breast cancer in humans. The research, conducted at the University of Pittsburgh Medical Center, has been hailed as a significant breakthrough by the US media.
Atilla Soran, a breast surgery oncologist and the principal investigator of the research, revealed that there has been considerable interest in the vaccination within the US. Currently, the vaccine is being tested on a group of 10 participants as part of a clinical study. The trial is expected to eventually include 50 participants. Soran emphasized that breast cancer is one of the most prevalent cancers affecting women, both in Turkey and globally.
Soran expressed confidence that the vaccine has the potential to prevent the spread of breast cancer throughout the body. He described the development of the vaccine, which has undergone years of laboratory testing and is now progressing towards clinical trials, as a significant achievement for the research team.
The participants in the trial will be closely monitored over the next five years, and the vaccine will only be approved for commercial use if it proves to be safe in larger clinical trials.
Soran highlighted that lung cancer is responsible for more female deaths than breast cancer. He stressed the importance of early diagnosis, as only a small percentage of Nigerian women diagnosed with breast cancer receive early detection. He recommended that all women over the age of 40 undergo mammograms annually, as this screening method has the potential to detect early-stage breast cancer in one or two out of every 1,000 women screened.
No comments:
Post a Comment